NFKB1 and cancer: NF-κB signaling is hyperactive in many cancers, including CRC; thus, discovery of its novel negative regulator, identifying ARMC4’s innovative role in CRC regulation, and delineating an exciting new avenue for a potential therapeutic approach to CRC holds great significance in the CRC research field.